Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Subjects Clear all
Completed Phase 2 Interventional Results available

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

NCT02130193
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

NCT05247528
View directory record Official record
Conditions
Resistant Hypertension, Difficult to Control Hypertension
Interventions
MANP, Placebo
Drug
Lead sponsor
E-Star BioTech, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Anniston, Alabama • Tustin, California • DeLand, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance

NCT00447811
View directory record Official record
Conditions
Methadone-maintenance Subjects
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

NCT05352893
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
750 mg Imsidolimab, 300 mg Imsidolimab, Placebo
Drug · Other
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

NCT03932864
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MGTA-145, plerixafor, Placebo
Biological
Lead sponsor
Ensoma
Industry
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 19, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

NCT00562887
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, ABT-874
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
36
States / cities
Orange, California • San Diego, California • Hamden, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

Study Evaluating AGG-523 in Subjects With Osteoarthritis

NCT00427687
View directory record Official record
Conditions
Osteoarthritis
Interventions
AGG-523
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Altoona, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 19, 2026, 11:23 AM EDT
Withdrawn Phase 2 Interventional

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

NCT04213274
View directory record Official record
Conditions
Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions
80 mg RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis

NCT01458574
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, CP690,550, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
94
States / cities
Mobile, Alabama • La Jolla, California • Oceanside, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Zinc Supplementation in Alcoholic Cirrhosis

NCT02072746
View directory record Official record
Conditions
Alcoholic Cirrhosis
Interventions
Zinc, Placebo
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

AZD6765 Severe Major Depressive Disorder (MDD) IV

NCT00781742
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 19, 2026, 11:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

NCT02639299
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab
Drug · Combination Product
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
57
States / cities
Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Results available

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

NCT01003691
View directory record Official record
Conditions
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
24
States / cities
Campbell, California • Los Gatos, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study of VGX-1027 in Healthy Subjects

NCT00760396
View directory record Official record
Conditions
Healthy
Interventions
VGX-1027
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 19, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

NCT00964990
View directory record Official record
Conditions
Pain, Neuralgia, Postherpetic, Neuralgia, Mononeuropathies
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Redondo Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

NCT03249103
View directory record Official record
Conditions
Fibromyalgia
Interventions
NYX-2925, Placebo oral capsule
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"

NCT02348593
View directory record Official record
Conditions
Narcolepsy
Interventions
JZP-110, Placebo oral tablet
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

NCT03934216
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BMS-986165, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Bristol, Connecticut • Gainesville, Florida • New Port Richey, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 19, 2026, 11:23 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 19, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03325010
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 19, 2026, 11:23 AM EDT